TY - JOUR
T1 - Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone
AU - Fiellin, David A.
AU - Weiss, Linda
AU - Botsko, Michael
AU - Egan, James E.
AU - Altice, Frederick L.
AU - Bazerman, Lauri B.
AU - Chaudhry, Amina
AU - Cunningham, Chinazo O.
AU - Gourevitch, Marc N.
AU - Lum, Paula J.
AU - Sullivan, Lynn E.
AU - Schottenfeld, Richard S.
AU - O'Connor, Patrick G.
PY - 2011/3/1
Y1 - 2011/3/1
N2 - Background: Buprenorphine/naloxone allows the integration of opioid dependence and HIV treatment. Methods: We conducted a prospective study in HIV-infected opioid-dependent patients to investigate the impact of buprenorphine/naloxone treatment on drug use. Self-report and chart review assessments were conducted every 3 months (quarters 1-4) for 1 year. Outcomes were buprenorphine/naloxone treatment retention, drug use, and addiction treatment processes. Results: Among 303 patients enrolled between July 2005 and December 2007, retention in buprenorphine/naloxone treatment was 74%, 67%, 59%, and 49% during Quarters 1, 2, 3, and 4, respectively. Past 30-day illicit opioid use decreased from 84% of patients at baseline to 42% in retained patients over the year. Patients were 52% less likely to use illicit opioids for each quarter in treatment (Odds ratio = 0.66; 95% CI: 0.61 to 0.72). Buprenorphine/naloxone doses and office visits approximated guidelines published by the United States Department of Health and Human Services. Urine toxicology monitoring was less frequent than recommended. Conclusions: Buprenorphine/naloxone provided in HIV treatment settings can decrease opioid use. Strategies are needed to improve retention and address ongoing drug use in this treatment population.
AB - Background: Buprenorphine/naloxone allows the integration of opioid dependence and HIV treatment. Methods: We conducted a prospective study in HIV-infected opioid-dependent patients to investigate the impact of buprenorphine/naloxone treatment on drug use. Self-report and chart review assessments were conducted every 3 months (quarters 1-4) for 1 year. Outcomes were buprenorphine/naloxone treatment retention, drug use, and addiction treatment processes. Results: Among 303 patients enrolled between July 2005 and December 2007, retention in buprenorphine/naloxone treatment was 74%, 67%, 59%, and 49% during Quarters 1, 2, 3, and 4, respectively. Past 30-day illicit opioid use decreased from 84% of patients at baseline to 42% in retained patients over the year. Patients were 52% less likely to use illicit opioids for each quarter in treatment (Odds ratio = 0.66; 95% CI: 0.61 to 0.72). Buprenorphine/naloxone doses and office visits approximated guidelines published by the United States Department of Health and Human Services. Urine toxicology monitoring was less frequent than recommended. Conclusions: Buprenorphine/naloxone provided in HIV treatment settings can decrease opioid use. Strategies are needed to improve retention and address ongoing drug use in this treatment population.
KW - Buprenorphine
KW - HIV
KW - heroin dependence
KW - methadone
KW - opioid-related disorders
UR - http://www.scopus.com/inward/record.url?scp=79951782548&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79951782548&partnerID=8YFLogxK
U2 - 10.1097/QAI.0b013e3182097537
DO - 10.1097/QAI.0b013e3182097537
M3 - Article
C2 - 21317592
AN - SCOPUS:79951782548
SN - 1525-4135
VL - 56
SP - S33-S38
JO - Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
JF - Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
IS - SUPPL. 1
ER -
